100
Participants
Start Date
November 30, 2002
Study Completion Date
November 30, 2003
somatropin
Somatropin will be administered as a daily subcutaneous injection; Fixed doses starting with 0.1 mg/day in patients older than 55 years or patients weighing less than 50 kg; all other patients: 0.1 mg/day or 0.2 mg/day (these doses should all be lower than 0.04 mg/kg/week); all patients starting at 0.1 mg/day will have their dose progressively increased in 0.1 mg/day increments to a maximum clinically- and pharmacologically- tolerated plateau dose; all patients starting at 0.2 mg/day will increase in 0.2 mg/day increments; all incremented dose changes will occur at monthly intervals based on IGF-I levels; treatment will continue for 12 months
Pfizer Investigational Site, Pittsburgh
Pfizer Investigational Site, El Paso
Pfizer Investigational Site, Salt Lake City
Pfizer Investigational Site, Federal Way
Lead Sponsor
Pfizer
INDUSTRY